Topic
Solid lipid nanoparticle
About: Solid lipid nanoparticle is a research topic. Over the lifetime, 3175 publications have been published within this topic receiving 127912 citations. The topic is also known as: LNP & SLN.
Papers published on a yearly basis
Papers
More filters
••
49 citations
••
TL;DR: This factorial design study has proven to be a useful tool in optimizing SLN (z-AVE ∼ 200 nm), which were shown to be non-cytotoxic and highlight the benefit of applying statistical designs in the preparation and optimization of SLN formulations.
48 citations
••
03 Jun 2013TL;DR: The obtained results are indicative of SLNs as potential lipid carriers for improving the bioavailability of quetiapine fumarate by minimizing first-pass metabolism.
Abstract: Quetiapine fumarate is an antipsychotic drug with poor oral bioavailability (9%) due to first-pass metabolism. Present work is an attempt to improve oral bioavailability of quetiapine fumarate by incorporating in solid lipid nanoparticles (SLN). Six quetiapine fumarate SLN formulations were developed using three different lipids by hot homogenisation followed by ultrasonication. The drug excipient compatibility was studied by differential scanning calorimetry (DSC). Stable quetiapine fumarate SLNs having a mean particle size of 200–250 nm with entrapment efficiency varying in between 80% and 92% were developed. The physical stability of optimized formulation F3 was checked at room temperature for 2 months. Comparative bioavailability studies were conducted in male Wistar rats after oral administration of quetiapine fumarate suspension and SLN formulation. The relative bioavailability of quetiapine fumarate from optimized SLN preparation was increased by 3.71 times when compared with the reference quetiapine fumarate suspension. The obtained results are indicative of SLNs as potential lipid carriers for improving the bioavailability of quetiapine fumarate by minimizing first-pass metabolism.
48 citations
••
TL;DR: The in vivo study confirmed the higher availability of VCZ (from SLN) in aqueous humor with minimal nasolacrymal drainage in contrast to the drug suspension, and a good in-vitro in- vivo correlation (IVIVC) further confirmed the potential of SLN as an effective carrier for ocular delivery.
Abstract: This research focuses on the fabrication and evaluation of solid lipid nanoparticles (SLNs) for improved ocular delivery of voriconazole (VCZ). Compritol and palmitic acid were selected as lipid carriers based on drug solubility and partitioning behavior. Poloxamer and soya lecithin were the choice for surfactant, while sodium taurocholate was used as a co-surfactant. The particle sizes of the SLNs determined by zetasizer and transmission electron microscopy (TEM) were found within the desired range. The in vitro release study of SLNs exhibited a sustained-release property of the drug. The ex vivo studies displayed enhanced corneal drug permeation from SLNs in comparison to the drug suspension. Further, the corneal hydration studies, histopathology and Hen's Egg Test Chorio Allantoic Membrane (HETCAM) assay confirmed the non-irritancy of the nano-formulation. The in vivo study confirmed the higher availability of VCZ (from SLN) in aqueous humor with minimal nasolacrymal drainage in contrast to the drug suspension. A good in-vitro in-vivo correlation (IVIVC) further confirmed the potential of SLN as an effective carrier for ocular delivery.
48 citations
••
TL;DR: To enhance shikonin-Act anti-proliferation properties, it was successfully incorporated in Solid Lipid Nanoparticles (SLNs) by the hot homogenization and entrapment efficiency of drug in SLNs was determined by ultrafiltration method.
48 citations